TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01666691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beloranib
Description: Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beloranib
Description: Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beloranib
Description: Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beloranib
Description: Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beloranib
Description: Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
Study: NCT02260466

Intervention type: OTHER
Group type: OTHER
Intervention: a basal LV septum biopsy
Description: During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
Study: NCT02399592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocotrinol
Description: 300 mg tid
Study: NCT01693133

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care: Moist Wound Therapy and Offloading
Description: Standard of Care: Moist Wound Therapy and Offloading

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EpiFix plus Standard of Care
Description: Weekly application of EpiFix and Standard of Care
Study: NCT04417725

Intervention type: OTHER
Intervention: Not applicable - this is a non-interventional, observational study.
Description: Not applicable - this is a non-interventional, observational study.

Intervention type: OTHER
Intervention: Not applicable - this is a non-interventional, observational study.
Description: Not applicable - this is a non-interventional, observational study.

Intervention type: OTHER
Intervention: Not applicable - this is a non-interventional, observational study.
Description: Not applicable - this is a non-interventional, observational study.
Study: NCT04212286

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic CEUS and EOB-MRI
Description: Undergo Sonovue-CEUS and EOB-MRI
Study: NCT06429878

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biparametric prostatic MRI

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biparametric prostatic MRI
Study: NCT00547638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cyanoacrylate with pressure sensitive mesh
Description: Topical Skin Adhesive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cyanoacrylate
Description: Topical Skin Adhesive
Study: NCT04110418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue
Description: Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylene Blue
Description: Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h
Study: NCT04557254

Intervention type: DEVICE
Intervention: graft
Description: evaluate the early and long-term clinical results, up to 5 years (through follow-up outpatient visits), of a silver and triclosan knitted collagen coated polyester vascular graft (InterGard Synergy), in patients submitted to aortic surgical repair, and compare them with concurrent results of standard Dacron grafts.

Intervention type: DEVICE
Intervention: graft
Description: evaluate the early and long-term clinical results, up to 5 years (through follow-up outpatient visits), of a silver and triclosan knitted collagen coated polyester vascular graft (InterGard Synergy), in patients submitted to aortic surgical repair, and compare them with concurrent results of standard Dacron grafts.
Study: NCT01423773

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon A test contact lens
Description: Silicone hydrogel single vision, soft contact lens with alternate parameters

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon A test contact lens
Description: Silicone hydrogel single vision, soft contact lens with alternate parameters

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon A control contact lens
Description: Silicone hydrogel single vision, soft contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon A control contact lens
Description: Silicone hydrogel single vision, soft contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultra-High Resolution Optical Coherence Tomographer (OCT)
Description: Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultra-High Resolution Optical Coherence Tomographer (OCT)
Description: Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear
Study: NCT00970957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin Intravitreal Injection
Description: Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin Intravitreal Injection
Description: Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Avastin Intravitreal Injection
Description: Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Avastin Intravitreal Injection
Description: Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
Study: NCT04585295

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine
Description: 50 mg/kg Betaine consumed twice daily for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine
Description: 50 mg/kg Betaine consumed twice daily for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine
Description: 50 mg/kg Betaine consumed twice daily for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA Big 6
Description: 1 level scoop (\~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA Big 6
Description: 1 level scoop (\~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA Big 6
Description: 1 level scoop (\~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50 mg/kg Placebo consumed twice daily for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50 mg/kg Placebo consumed twice daily for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50 mg/kg Placebo consumed twice daily for 7 days.
Study: NCT06373172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual simulation-based education program
Description: We used vSim® for Nursing - Nursing Medical-Surgical as the virtual simulation-based education program. Four modules were included: (a) acute myocardial infarction, (b) diabetes mellitus, (c) transfusion, and (4) asthma. Each module learning sessions was conducted based on scenarios, which consisted of five steps: Suggested reading, Pre-simulation quiz, vSim, Post-simulation quiz, and Guide reflection questions. For each module, the intervention was performed for two hours. The participants attended four module learning sessions and received eight hours of training. Debriefing using guided reflection questions were completed in the form of a team reflection, followed by an instructor-learner discussion and feedback for 20 minutes of each module.
Study: NCT00165841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole 20 mg
Description: rabeprazole sodium tablet 20 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Description: rabeprazole sodium tablet 20 mg once daily
Study: NCT01502982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOEP14x6+HD-AraC+HD-Mtx
Description: rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
Study: NCT03348852

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
Study: NCT00301028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Beginning weekly dose 400 mg/m\^2 IV over 1-2 hours, and 250 mg/m\^2 weeks 2-6.
Study: NCT04297995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: 5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET
Study: NCT04297995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.
Study: NCT03903159

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive Peer Journaling (PPJ)
Description: PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health.
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study: NCT00301028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 weekly for 6 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135 mg/m\^2 weekly for 6 courses.
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study: NCT04001842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction of the mandible using an axially vascularized bone construct
Description: Surgically reconstructing defects of the mandible using reconstruction plate and Titanium mesh filled with an artificial bone substitute to form a bone construct. This construct will be vascularized at the same operation using a vein graft from the forearm. The vein graft will be microsurgically connected to an artery and vein within the facial/neck region to provide a vascular supply to the construct (arterio venous loop)
Study: NCT05041985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Tablets
Description: Diazepam 5 mg tablet once per day (bedtime) for 7 days
Study: NCT01295489

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01323192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNS001
Description: Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo orally once daily for 8 weeks.
Study: NCT04092634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual mobility implant
Description: Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional, Single-bearing hip implant
Description: Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
Study: NCT01246960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered intravenously
Study: NCT00301028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Following induction in second part of study.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Following induction in second part of study.
Study: NCT00231244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER Sirolimus-Eluting Coronary Stent
Description: CYPHER Sirolimus-Eluting Coronary Stent
Study: NCT00423735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03822572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endurance exercise
Description: defined exercise program

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: habitual physical activity before the diagnosis
Study: NCT01841437

Intervention type: DEVICE
Intervention: iStent
Study: NCT00835952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: ATX-101 single doses
Study: NCT01384240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulfate
Description: 3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
Study: NCT02671942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01919905

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
Study: NCT01887392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Translation Education Sessions
Description: Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Translation Education Sessions
Description: Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
Study: NCT03751891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audéo B90-Direct
Description: The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HearingAid_A
Description: HearingAid_A is the most recent Receiver-in-the-canal Hearing aid from manufacturer_A which will be fitted to the participants individual Hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HearingAid_B
Description: HearingAid_B is the most recent Receiver-in-the-canal Hearing aid from manufacturer_B which will be fitted to the participants individual Hearing loss.